3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow KLH: new trials by email Literature Review of KLH trials Research Report on KLH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 2 | Completed | Celldex Therapeutics | 127 | 2011-12-01 | 2020-02-17 |
| Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4 - Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL) | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2008-02-22 | 2017-04-12 |
| Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome Bacteriophage, rhuCD40L, KLH - Immunoproliferative Disorder | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 1999-10-01 | 2008-03-04 |
Brain Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Immunodeficiency Diseases (1) · Recurrence (1)
Celldex Therapeutics (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (3)